M&A Deal Summary |
|
|---|---|
| Date | 2025-02-26 |
| Target | BioSymetrics |
| Sector | Life Science |
| Buyer(s) | Renovaro Biosciences |
| Deal Type | Merger |
SEARCH BY
| Category | Company |
|---|---|
| Sector | Life Science |
| Employees | 25 |
| Revenue | 19.6B USD (2023) |
Renovaro Biosciences has developed advanced cell, gene and immunotherapy platforms designed to renew the body's natural tumor-fighting capabilities against cancer and infectious diseases. Renovaro Biosciences is based in Los Angeles, California.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 4 |
| Sector: Life Science M&A | 4 of 4 |
| Type: Merger M&A Deals | 1 of 1 |
| State: New York M&A | 1 of 1 |
| Country: United States M&A | 2 of 2 |
| Year: 2025 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-01-06 |
Predictive Oncology
Eagan, Minnesota, United States Predictive Oncology operates through three segments (Domestic, International, and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical, and Skyline Europe. Predictive Oncology was founded in 2002 and is based in Eagan, Minnesota. |
Buy | - |
